Factor VIII and IX deficiencies related to acquired inhibitors in a patient with chronic hepatitis C virus infection receiving treatment with pegylated interferon plus ribavirin

Marilza Campos‐de‐MagalhãesHematology Unit – Medical Clinic ‘B’Gaffrée & Guinle University Hospital, School of Medicine and Surgery, Federal University of the State of Rio de Janeiro, Brazil

Carlos Eduardo Brandão‐MelloLiver Diseases Unit – Medical Clinic ‘A’Gaffrée & Guinle University Hospital, School of Medicine and Surgery, Federal University of the State of Rio de Janeiro, Brazil

Maria Lúcia Elias PiresEndocrinology Unit – Medical Clinic ‘A’Gaffrée & Guinle University Hospital, School of Medicine and Surgery, Federal University of the State of Rio de Janeiro, Brazil

Maria Cecília da Fonseca SalgadoRheumatology Unit – Medical Clinic ‘B’Gaffrée & Guinle University Hospital, School of Medicine and Surgery, Federal University of the State of Rio de Janeiro, Brazil

Selma Barcelo de BritoHemostasis and Thrombosis LaboratoryArthur de Siqueira Cavalcanti State Hematology Institute (HEMORIO), Rio de Janeiro, Brazil

Adilson José de AlmeidaHematology Unit – Medical Clinic ‘B’Gaffrée & Guinle University Hospital, School of Medicine and Surgery, Federal University of the State of Rio de Janeiro, BrazilCorrespondence[email protected]

Factor VIII and IX deficiencies related to acquired inhibitors in a patient with chronic hepatitis C virus infection receiving treatment with pegylated interferon plus ribavirin

Table 1. Patient’s laboratory characteristics during pretreatment evaluation

Table 2. Patient’s laboratory characteristics during and after completion of antiviral therapy with pegylated interferon plus ribavirin

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Factor VIII and IX deficiencies related to acquired inhibitors in a patient with chronic hepatitis C virus infection receiving treatment with pegylated interferon plus ribavirin

Figures & data

Table 1. Patient’s laboratory characteristics during pretreatment evaluation

Table 2. Patient’s laboratory characteristics during and after completion of antiviral therapy with pegylated interferon plus ribavirin

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date